Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome
Testing ACS patients for KIF6 carrier status may be a cost-effective strategy at commonly accepted thresholds. Treating all patients with A80 is more expensive than treating patients on the basis of KIF6 results, but the modest gain in QALYs is achieved at a cost/QALY that is generally considered unacceptable compared with the KIF6 Testing strategy. Compared with treating all patients with P40, the KIF6 Testing strategy had an ICER below US$50,000 per QALY. The conclusions from this study are sensitive to the price of generic A80 and the effect on adherence of knowing KIF6 carrier status. The results were based on a post hoc substudy of the PROVE IT trial, which was not designed to test the effectiveness of KIF6 testing. </AbstractSection> Copyright Springer International Publishing Switzerland 2013
Year of publication: |
2013
|
---|---|
Authors: | Parthan, Anju ; Leahy, Kevin ; Amy O’Sullivan ; Iakoubova, Olga ; Bare, Lance ; Devlin, James ; Weinstein, Milton |
Published in: |
PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 31.2013, 6, p. 519-531
|
Publisher: |
Springer |
Saved in:
Saved in favorites
Similar items by person
-
Parthan, Anju, (2013)
-
EXPLORATION & DEVELOPMENT - Caribbean source rocks may point toward buried treasure
Leahy, Kevin, (2004)
-
Brand architecture in services : the example of retail financial services
Devlin, James, (2010)
- More ...